Drug-coated balloon catheters for body lumens
Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.
1. A method for treatment of a anastomotic stricture, the method comprising:
flushing the anastomotic stricture with a flushing media comprising water, saline solution, or a water solution comprising at least one water-soluble additive;
inserting a balloon catheter into a target site in a body lumen comprising the anastomotic stricture, the balloon catheter comprising
an elongated balloon, and
a coating layer overlying an exterior surface of the balloon, wherein the coating layer comprises an initial drug load of a therapeutic agent;
exposing the balloon catheter to a liquid comprising the flushing media in the anastomotic stricture for a soaking period prior to inflation to hydrate the coating layer;
inflating the balloon at the target site to contact the coating layer with walls of the body lumen at the location of the anastomotic stricture until the balloon achieves an inflated balloon diameter for an inflation period;
deflating the balloon after the inflation period; and
withdrawing the balloon catheter from the body lumen.
2. The method of claim 1 , wherein the anastomotic stricture is a non-vascular stricture.
3. The method of claim 1 , wherein exposing the balloon catheter to the liquid comprises holding the balloon catheter in position for the soaking period prior to inflation to hydrate the coating layer.
4. The method of claim 1 , wherein the balloon has thereon a residual drug amount after the withdrawing, wherein the residual drug amount is 70% or less of the initial drug load.
5. The method of claim 1 , wherein the soaking period in combination with the contacting of the coating layer with the stricture is sufficient to release 37% to 97% of the initial drug load.
6. The method of claim 1 , wherein the soaking period is predetermined prior to the exposing of the balloon catheter to the liquid.
7. The method of claim 1 , wherein the soaking period comprises at least 1 minute.
8. The method of claim 1 , wherein the inserting is prior to, during, or after the flushing of the anastomotic stricture.
9. The method of claim 1 , wherein the flushing is prior to the inserting of the balloon catheter into the anastomotic stricture.
10. The method of claim 1 , wherein the balloon catheter comprises an elongated balloon having a main diameter, the elongated balloon comprising at least one neck section, the balloon comprising a first main section and a second main section on opposite sides of the neck section.
11. The method of claim 10 , wherein the at least one neck section comprises an inflated diameter that is smaller than the main diameter when the balloon is inflated, during the inflating the inflated diameter of the neck section is the smallest diameter of the balloon catheter between the first main section and the second main section, during the inflating the inflated diameter of the neck section is greater than a diameter of the neck section prior to the inflation, and the at least one neck section comprises an area of reduced compliance during inflation relative to the first main section and the second main section.
12. The method of claim 10 , wherein the drug coating is on the first main section and the neck.
13. The method of claim 10 , wherein the inflating comprises inflating the first section, the second section, and the neck section of the balloon simultaneously via a single inflation lumen.
14. The method of claim 10 , wherein the at least one neck section comprises a reinforcing material around a circumference of the neck section to reduce compliance of the neck section during the inflation.
15. The method of claim 14 , wherein the reinforcing material comprising a suture, monofilament, or multifilament, wherein the reinforcing material comprises nylon, a polyamide, an aromatic polyamide, ultra high molecular weight polyethylene (UHMWPE), a polyester, an aromatic polyester, polyethylene terephthalate (PET), or a combination thereof.
16. The method of claim 1 , wherein inserting the balloon catheter into the target site in the body lumen comprises inserting the balloon catheter and a scope into the target site in the body lumen.
17. The method of claim 16 , wherein the balloon catheter and the scope are positioned side-by-side or the balloon catheter is loaded into the scope.
18. The method of claim 16 , wherein the balloon catheter and the scope are positioned side-by-side.
19. The method of claim 16 , wherein the balloon catheter is loaded into the scope.
20. The method of claim 19 , wherein the balloon is positioned within a working channel of the scope prior to inserting the scope into the body lumen.
21. The method of claim 19 , wherein the balloon is positioned within a working channel of the scope after inserting the scope into the body lumen.
22. The method of claim 16 , wherein balloon catheter is visualizable with the scope.
23. The method of claim 16 , further comprising visualizing the balloon catheter with the scope before and/or during the inflating.
24. The method of claim 16 , further comprising visualizing the therapeutic agent that deposits from the balloon onto the anastomotic stricture via the scope.
25. The method of claim 16 , wherein the scope comprises an endoscope, enteroscope, colonoscope, sigmoidoscope, rectoscope, anoscope, rhinoscope, bronchoscope, or a cystoscope.
26. The method of claim 1 , wherein the therapeutic agent is chosen from paclitaxel, docetaxel, taxol, rapamycin, sirolimus, zotarolimus, everolimus, tacrolimus, mTOR inhibitors, analogues thereof, and combinations thereof.